search
Back to results

Remote Myocardial Ischemic Preconditioning in Humans (RemoteMIPH)

Primary Purpose

Coronary Artery Ischemia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Blood pressure cuff
blood pressure cuff
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Ischemia focused on measuring Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease, Coronary Occlusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients will be eligible for randomization if they meet the following criteria:

    1. Age ≥ 18 years
    2. Clinically indicated elective or urgent PCI

Exclusion Criteria:

  • Patients will be ineligible for the study if one or more of the following conditions exist:

    1. Pre-PCI Troponin T ≥ 0.03
    2. Systemic hypotension (systolic <90 mmHg) or cardiogenic shock
    3. Presence of an arteriovenous fistula or lymphedema of either arm
    4. Currently enrolled in other active cardiovascular investigational studies
    5. Severe endocrine, hepatic, renal, disorders
    6. Pregnancy or lactation
    7. Inability to provide consent
    8. Federal Medical Center inmates
    9. Inability or unwillingness to provide informed consent

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

1

2

Arm Description

Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes

3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia

Outcomes

Primary Outcome Measures

Post PCI myonecrosis measured as a maximum troponin T ≥0.03

Secondary Outcome Measures

Post PCI myonecrosis measured as an elevation in creatine kinase MB fraction (CK-MB> 1 X upper limit of normal)
Magnitude of ST segment elevation on an intracoronary electrocardiogram during balloon inflation
Coronary perfusion measured as coronary flow reserve derived from TIMI frame counts
Blood high sensitivity C-reactive protein level
Blood endothelial progenitor cell counts (EPC)

Full Information

First Posted
December 21, 2007
Last Updated
April 15, 2019
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT00588042
Brief Title
Remote Myocardial Ischemic Preconditioning in Humans
Acronym
RemoteMIPH
Official Title
Remote Myocardial Ischemic Preconditioning in Humans
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.
Detailed Description
Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. We will also test the hypotheses that IP diminishes the inflammatory response to PCI, and that higher baseline blood endothelial progenitor cell counts are predictive of a favorable response to IP. Aim 1: To evaluate whether remote ischemic preconditioning reduces the frequency of myonecrosis (troponin T≥0.03 ng/ml following PCI). Aim 2: To evaluate whether remote ischemic preconditioning reduces the inflammatory response to PCI (post PCI hsCRP level). Aim 3: To evaluate whether pre-procedure circulating endothelial progenitor cell counts correlate with the effect of remote ischemic preconditioning on myonecrosis. Background: Percutaneous coronary intervention (PCI) frequently results in ischemic myonecrosis. Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. Aims: The aims of the study are to assess in patients with coronary artery disease requiring PCI, whether remote IP reduces: 1) the frequency of myonecrosis; and 2) the inflammatory response to PCI; and 3) whether the effect of IP correlates with pre-procedure circulating endothelial progenitor cell counts. Methods: The study is a prospective, randomized trial to assess the efficacy of remote IP as adjunctive non-pharmacological therapy for PCI in patients with stable or unstable angina. Remote IP will be performed by 3 cycles of 3-minutes of arm ischemia alternating with 3- minutes of reperfusion of the arm immediately before PCI. Myonecrosis and inflammation will be detected by measuring serum troponin T and high sensitivity C-reactive protein, respectively. Blood EPC counts will also be measured before the procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Ischemia
Keywords
Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease, Coronary Occlusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
156 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
Arm Title
2
Arm Type
Sham Comparator
Arm Description
3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
Intervention Type
Device
Intervention Name(s)
Blood pressure cuff
Other Intervention Name(s)
sphygmomanometer
Intervention Description
Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
Intervention Type
Device
Intervention Name(s)
blood pressure cuff
Other Intervention Name(s)
sphygmomanometer
Intervention Description
3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
Primary Outcome Measure Information:
Title
Post PCI myonecrosis measured as a maximum troponin T ≥0.03
Time Frame
16 hours post PCI
Secondary Outcome Measure Information:
Title
Post PCI myonecrosis measured as an elevation in creatine kinase MB fraction (CK-MB> 1 X upper limit of normal)
Time Frame
16 hours post procedure
Title
Magnitude of ST segment elevation on an intracoronary electrocardiogram during balloon inflation
Time Frame
During PCI procedure
Title
Coronary perfusion measured as coronary flow reserve derived from TIMI frame counts
Time Frame
During PCI
Title
Blood high sensitivity C-reactive protein level
Time Frame
Immediately prePCI
Title
Blood endothelial progenitor cell counts (EPC)
Time Frame
Immediately prePCI

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for randomization if they meet the following criteria: Age ≥ 18 years Clinically indicated elective or urgent PCI Exclusion Criteria: Patients will be ineligible for the study if one or more of the following conditions exist: Pre-PCI Troponin T ≥ 0.03 Systemic hypotension (systolic <90 mmHg) or cardiogenic shock Presence of an arteriovenous fistula or lymphedema of either arm Currently enrolled in other active cardiovascular investigational studies Severe endocrine, hepatic, renal, disorders Pregnancy or lactation Inability to provide consent Federal Medical Center inmates Inability or unwillingness to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abhiram Prasad, MBBS
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22517646
Citation
Prasad A, Gossl M, Hoyt J, Lennon RJ, Polk L, Simari R, Holmes DR Jr, Rihal CS, Lerman A. Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv. 2013 May;81(6):930-6. doi: 10.1002/ccd.24443. Epub 2012 Nov 8.
Results Reference
result
Links:
URL
http://clinicaltrials.mayo.edu
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Remote Myocardial Ischemic Preconditioning in Humans

We'll reach out to this number within 24 hrs